Duncan Mchale serves as Executive at Evelo Biosciences, Inc., where they oversee executive responsibilities. Since joining the company, Duncan Mchale has executed 9 insider transactions totaling $94.6K, demonstrating a bullish approach to their equity position. Their most recent transaction on Nov 8, 2023 involved selling 3,103 shares valued at $1.0K.
Duncan Mchale currently holds 16,984 shares of Evelo Biosciences, Inc. (EVLO), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Duncan Mchale has been a net buyer of EVLO stock. They have purchased $50.0K and sold $44.6K worth of shares.
Duncan Mchale's most recent insider trade was on Nov 8, 2023, when they sold 3,103 shares at $0.33 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Planned |
| Nov 2, 2023 | EVLO | $2.3K | Sale | 6,854 | $0.33 | Planned |
| Nov 1, 2023 | EVLO | $0 | Option Exercise | 12,500 | $N/A | Planned |
| Aug 8, 2023 | EVLO | $32.7K | Sale | 3,434 | $9.51 | Planned |
| Aug 7, 2023 | EVLO | $0 | Option Exercise | 6,500 | $N/A | Planned |
| May 8, 2023 | EVLO | $8.7K | Sale | 66,730 | $0.13 | Planned |
| May 7, 2023 | EVLO | $0 | Option Exercise | 130,000 | $N/A | Discretionary |
| May 27, 2022 | EVLO | $50.0K | Purchase | 34,246 | $1.46 | Discretionary |